Dr. Anderson is Professor at Harvard Medical School, an adjunct Professor at MIT, and Director of the Wellman Center for Photomedicine at Massachusetts General Hospital in Boston, the world's largest academic facility dedicated to the use of light for diagnosis and therapy. He conceived and developed dermatologic surgery using selectively-absorbed laser pulses, which is now the preferred basis for treatment of birthmarks, pigmented lesions, tattoos, hypertrichosis and other conditions. Active research includes diagnostic tissue imaging and spectroscopy, photodynamic therapy, mechanisms of laser-tissue interactions, and novel therapy for skin disorders. Dr. Anderson received his undergraduate degree from MIT and his M.D. from Harvard Medical School through the MIT-Harvard Health Sciences and Technology program.
Mr. Crane is General Partner at Polaris Venture Partners, as well as Chairman of Cerulean Pharma, Inc., where he was CEO from 2006 to 2009. From 2002 until 2006, Mr. Crane was President and CEO of Momenta Pharmaceuticals (NASDAQ: MNTA). He joined Momenta as the fifth employee and built the company into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with the Sandoz division of Novartis, and raising $275 million. Prior to this, Mr. Crane was senior vice president of global corporate development at Millennium Pharmaceuticals, where he was responsible for leading Millennium's strategic partnering, mergers and acquisitions, and licensing activities, generating over $2 billion in partner funding and acquiring 19 development stage products. Prior to Millennium, Mr. Crane was a marketing executive at Dupont-Merck and a consultant with the Boston Consulting Group and Arthur D. Little. Mr. Crane serves on the boards of Momenta Pharmaceuticals, T2 Biosystems, Hydra Biosciences, Cerulean Pharma (Chair), Parasol Therapeutics (Chair) and Vaccinex. He previously served on the boards of Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by GlaxoSmithKline) and Adnexus (acquired by Bristol-Myers Squibb). He received his M.B.A. in 1992 and his B.A. summa cum laude and M.A. in 1986, all from Harvard University.
Mr. Hutt is a senior counsel in the Washington, D.C. law firm of Covington & Burling specializing in food and drug law. Mr. Hutt served as Chief Counsel for the Food and Drug Administration during 1971-1975. He is the co-author of the casebook used to teach Food and Drug Law throughout the country and teaches a course on the subject at Harvard Law School. Mr. Hutt has been a member of the Institute of Medicine since it was founded in 1971. He serves on government, academic, and venture capital advisory boards, and the boards of numerous startup biotechnology companies. He was named by The Washingtonian magazine as one of Washington's 50 best lawyers (out of more than 40,000) and as one of Washington's 100 most influential people; by the National Law Journal as one of the 40 best health care lawyers in the United States; and by European Counsel as the best FDA regulatory specialist in Washington, D.C.
Dr. Langer is one of 14 Institute Professors at MIT, and has done pioneering work in the areas of biomaterials, drug delivery, and bioengineering, most recently applying nanotechnology to the development of novel diagnostics and therapeutics. Professor Langer has written over 1050 articles and has over 700 issued or pending patents worldwide. Dr. Langer's patents have been licensed or sublicensed to over 180 pharmaceutical, chemical, biotechnology and medical device companies. He is a founder of over 20 successful companies, including Momenta Pharmaceuticals, Advanced Inhalation Research (AIR), Transform Pharmaceuticals, T2 Biosystems, BIND Biosciences, and Selecta Biosciences. Professor Langer is one of very few people ever elected to all three United States National Academies and the youngest in history (at age 43) to ever receive this distinction. In July 2007, he was awarded the National Medal of Science, the highest civilian honor bestowed by the United States. Dr. Langer received his B.S. from Cornell University, and his Sc.D. from the Massachusetts Institute of Technology, both in Chemical Engineering.
Anupendra Sharma is Senior Investment Partner at Siemens Venture Capital (SVC) in Boston, where he is responsible for investing in healthcare (devices, diagnostics, software and services). He serves on the Boards of Seventh Sense and Reflectance Medical. He invested in Sequenom (NASD: SQNM), China Diagnostics Medical (acquired by Actis & Orbimed), BioImagene (acquired by Roche) and Cylex (acquired by Viracor-IBT) and supported the investment in U-Systems (acquired by GE). Prior to SVC, Anupendra worked in investment banking and M&A for eight years at JPMorgan, Citigroup and Siemens. Anupendra holds an MBA from Cornell University, MS in Accounting & Finance from Manchester Business School, and Masters in Economics and Bachelors in Instrumentation Engineering, both from BITS Pilani, India.
Mr. Weisman is an accomplished entrepreneur in the life sciences industry and prior to joining Seventh Sense, he was the founder, Chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company focused in the hospital critical care market. Mr. Weisman was also co-founder of ESP Pharma where he served as a director in addition to the company's President and COO until its sale to PDL Biopharma in 2005. He began his career in sales and marketing at Merck and Co, Inc. and later moved to Parke-Davis where he launched that company's diabetes franchise in 1997. Mr. Weisman graduated with a BA in Chemistry from Rutgers University.
Mr. Wilcox joined Flagship Ventures in 2006, bringing a rich set of experiences and expertise in financial management, operations, fund management and strategy. As COO and General Partner at Flagship Ventures, Mr. Wilcox oversees the firm's financial operations and LP relations/fundraising, and serves as board member or advisor to select portfolio companies. Mr. Wilcox is currently a board member of Black Duck, Celexion, Seahorse Bioscience, T2 Biosystems and Tangent Medical.
Mr. Wilcox's career spans 30 years and has involved many different roles and functions including Controller, CFO, Sr. VP BD, and CEO. He has also served on several Boards of Directors. Most recently he has served as CFO and then Sr. VP Corporate Development for EXACT Sciences (NASDAQ:EXAS), one of Flagship's portfolio companies, and on the Board of another portfolio company, Epitome Biosystems.
In addition to his corporate experience, Mr. Wilcox was previously CFO of two venture capital firms, Highland Capital Partners where he was the founding CFO and General Partner, and prior to that, Charles River Ventures. Mr. Wilcox has also led an active consulting practice, which included roles as interim CEO of biotech companies Thrasos Therapeutics and Biostratum. Mr. Wilcox earned a BS in finance from the University of Arizona and an MBA from Boston University School of Management.